SENATE FILE NO. SF0134

Health insurance-clinical trials coverage.

Sponsored by: Senator(s) Hastert, Johnson, Massie, Ross and Sessions and Representative(s) Cohee, Iekel, Martin, Millin, Slater and Throne

A BILL

for

- 1 AN ACT relating to insurance; requiring coverage in health
- 2 insurance policies for claims arising from the insured's
- 3 receipt of treatment as part of a clinical trial or study
- 4 as specified; providing exceptions; and providing for an
- 5 effective date.

6

7 Be It Enacted by the Legislature of the State of Wyoming:

8

9 **Section 1.** W.S. 26-20-301 is created to read:

10

- 11 ARTICLE 3
- 12 CLINICAL TRIALS COVERAGE

13

- 14 26-20-301. Clinical trials and studies coverage
- 15 required.

16

23

1 (a) All individual and group health insurance policies providing coverage on an expense incurred basis, 2 3 individual and group service or indemnity type contracts 4 issued by any insurer including any nonprofit corporation 5 and individual and group service contracts issued by a health maintenance organization which provide coverage for 6 treatment of cancer shall also provide coverage for medical 7 treatment which a policyholder or certificate holder 8 9 receives as part of a clinical trial or study if: 10 11 (i) The medical treatment is provided in a phase I, phase II, phase III or phase IV study or clinical trial 12 13 for the treatment of cancer; 14 15 (ii) The clinical trial or study is approved by: 16 17 (A) An agency of the national institutes of health as set forth in 42 U.S.C. 281(b); 18 19 20 (B) The United States food and drug 21 administration as an application for a new investigational 22 drug;

2

1	(C) The United States department of
2	veterans affairs; or
3	
4	(D) The United States department of
5	defense.
6	
7	(iii) The medical treatment is provided by a
8	health care provider and the facility and personnel have
9	the experience and training to provide the treatment in a
LO	competent manner;
L1	
L2	(iv) There is a reasonable expectation based on
L3	clinical data that the medical treatment provided in the
L4	clinical trial or study will be at least as effective as
L5	any other medical treatment; and
L6	
L7	(v) The participant in the clinical trial or
L8	study, before commencing participation, has signed a
L9	statement of consent indicating that the participant has
20	been informed of:
21	
22	(A) The procedure to be undertaken;
23	
24	(B) Alternative methods of treatment; and

1

2 (C) The general nature and extent of risks

3 associated with participation in the clinical trial or

4 study.

5

6 (b) Coverage for medical treatment required by this

7 section shall be limited to:

8

9 (i) Coverage for any drug or device that is

10 approved for sale by the United States food and drug

11 administration without regard to whether the approved drug

12 or device has been approved for use in the study

13 participant's medical treatment;

14

15 (ii) The cost of any reasonably necessary health

16 care services that are required as a result of the medical

17 treatment provided in the clinical trial or study or as a

18 result of any complication arising out of the medical

19 treatment provided in the clinical trial or study, to the

20 extent that such health care services would otherwise be

21 covered under the policy or certificate of insurance;

22

4

1 (iii) The initial consultation to determine whether the policyholder or certificate holder is eligible 2 3 to participate in the clinical trial or study; 4 5 (iv) Health care services required for the 6 clinically appropriate monitoring of the policyholder or 7 subscriber during the clinical trial or study. 8 9 (c) The coverage required by this section does not 10 include: 11 12 (i) Any portion of the clinical trial or study 13 that is customarily paid for by a government or a 14 biotechnical, pharmaceutical or medical industry; 15 16 (ii) Coverage for any drug or device that is 17 paid for by the manufacturer, distributor or provider of the drug or device; 18 19 20 (iii) Health care services that are customarily 21 provided by the sponsors of the clinical trial or study 22 free of charge to the participants in the trial or study; 23

5

1 (iv) Extraneous expenses related to 2 participation in the clinical trial or study including, 3 without limitation, travel, housing and other expenses that 4 a participant or person accompanying a participant may 5 incur; 6 7 (v) Any item or service that is provided solely to satisfy a need or desire for data collection or analysis 8 9 that is not directly related to the clinical management of 10 the policyholder or subscriber; 11 12 (vi) Any costs for the management of research 13 relating to the clinical trial or study. 14 15 (d) Nothing in this section precludes an insurer from 16 excluding coverage for any claim arising from the practice 17 of medicine or other health care by a person without an applicable physician or health care provider license. 18 19 20 Section 2. This act is effective July 1, 2007. 21 22 (END)